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The importance of vitamin D in immunologic processes has recently emerged, but whether it has any impact
on the course of allogeneic hematopoietic stem cell transplantation (HSCT) has not been determined. Reports
indicate that HSCT recipients, particularly children, often suffer from vitamin D deﬁciency. This study
investigated the role of vitamin D in 123 children undergoing HSCT from 2004 to 2011. Vitamin D (ie, serum
calcidiol) was analyzed in collected cryostored samples. Patients were grouped according to pre-HSCT cal-
cidiol level: insufﬁcient (<50 nm/L, n ¼ 38) and sufﬁcient (50 nm/L, n ¼ 85). Older children who underwent
transplants from January through June and children of Middle Eastern or African origin were more commonly
found in the insufﬁcient group. Acute grades II to IV graft-versus-host disease occurred more frequently in the
vitamin D sufﬁcient group (47% versus 30%, P ¼ .05), whereas no difference was demonstrated for chronic
graft-versus-host disease. The neutrophil granulocytes rose signiﬁcantly faster in the vitamin D sufﬁcient
group. No difference in lymphocyte counts, immunoglobulin levels, or infectious disease burden during the
ﬁrst year post-HSCT were observed. Among children with malignancies, overall survival was signiﬁcantly
better in the sufﬁcient group (87% versus 50%, P ¼ .01). In addition, rejection (0% versus 11%, P ¼ .06) and
relapse (4% versus 33%, P ¼ .03) rates were lower in patients with sufﬁcient vitamin D levels. To conclude,
vitamin D may have an important impact on the outcome of pediatric HSCT, particularly in patients with
malignant disease. Further studies investigating whether vitamin D acts as an immunomodulator or is merely
a surrogate marker of patient health or nutritional status are warranted.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
The importance of micronutrients, including vitamin D, in
immunologic processes has emerged in recent years. An as-
sociation between vitamin D insufﬁciency and a variety of
infections (eg, tuberculosis and respiratory tract infections)
has been reported [1,2], along with the biologic effects of
vitamin D beyond its hormonal activity in calcium homeo-
stasis, including a role in both innate and adaptive immune
responses [3-5].
Whether vitamin D status affects the course or outcome
of allogeneic hematopoietic stem cell transplantation (HSCT)dgments on page 1542.
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14.05.030has not been fully established. Previous data suggest that
vitamin D might prevent graft-versus-host disease (GVHD).
Vitamin D exposure also resulted in immature dendritic cell
populations with bias toward tolerizing rather than stimu-
latory T-lymphocyte populations, which could provide a
possible mechanism for its beneﬁcial effects against GVHD
[6,7]. Humans attain vitamin D mainly from exposure to
sunlight and to a lesser extent from dietary sources. After
HSCT, children’s exposure to direct sunlight is restricted, and
they might also suffer from poor nutrition and malabsorp-
tion due to HSCT-related side effects. An increased catabo-
lism because of the use of glucocorticoids and other
immunesuppressants could also affect vitamin D levels in
serum [8]. Low vitamin D levels in children undergoing HSCT
have been reported, but these data were not related to
clinical outcome [9].Transplantation.
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precisely deﬁned given uncertainties regarding the rela-
tionship between vitamin D levels and various clinical
endpoints. A sufﬁcient level of vitamin D can be deﬁned
as serum calcidiol 50 nmol/L, because this level is
believed to cover the needs of 97.5% of the population
[10]. The role of vitamin D in the context of pediatric HSCT
remains elusive, and therefore the main objective of this
study was to evaluate whether vitamin D levels were
associated with short- and long-term outcome parame-
ters in pediatric HSCT.Table 1
Patient Characteristics (N ¼ 123)
Characteristic
<50 nM (n ¼ 85)
Age, yr, median (range) 10 (0-19)
Sex (male/female), n 57 (67%)/28 (33%
BMI, median (range) 18.5 (12.0-45.1)
Ethnic origin, n
European 57 (67%)
African 9 (11%)
Middle Eastern 16 (19%)
Other 3 (4%)
Diagnosis, n
Nonmalignant 42 (49%)
AML/ALL 8/22 (9%/26%)
CML 3 (4%)
Lymphoma 3 (4%)
MDS 7 (8%)
Other 0
Disease stage Early/late,* n 58 (68%)/27 (32%
Conditioning, n
fTBI þ Cy 26 (31%)
Bu þ Cy 30 (35%)
Flu þ Bu 2 (2%)
Flu þ Cy 7 (8%)
Flu þ fTBI þ Cy 4 (5%)
Flu þ Treo 16 (19%)
ATG 67 (79%)
Donor
Age, yr (range) 22 (0-55)
Female to male, n 20 (24%)
MRD, n 29 (34%)
MUD, n 38 (45%)
MM, n 18 (21%)
Stem cell source, n
Bone marrow 55 (65%)
PBSC 16 (19%)
Cord blood 14 (16%)
Cell dose
Nucleated cells,  108/kg 4.1 (.3-37)
CD34 cells,  106/kg 4.8 (.1-44)
GVHD prophylaxis, n
CsA þ MTX 52 (61%)
CsA þ prednisolone 12 (14%)
Tacrolimus þ sirolimus 18 (21%)
Other 3 (3.5%)
aGVHD, n
None 46 (54%)
Grade I 14 (16%)
Grades II-IV 25 (29%)
cGvHD, yes/no 11/73
IgG replacement, n 48 (56%)
Vitamin D substitution, n 25 (29%)
Lansky/Karnofsky score,y mean (range) 86 (60-100)
BMI indicates body mass index; AML, acute myeloid leukemia; ALL, acute lymph
syndrome; fTBI, fractionated total body irradiation; Cy, cyclophosphamide; Bu,
serotherapy; MRD, HLA-matched related donor; MUD, HLA-matched unrelated do
cyclosporine A; MTX, methotrexate.
* Early ¼ ﬁrst complete remission/ﬁrst chronic phase and nonmalignant.
y Lansky scale were used for children <16 and Karnofsky scale for those 16 yeMETHODS
Patients
Between June 2004 and December 2011, 163 pediatric patients un-
derwent HSCT at our center at the Karolinska University Hospital in Hud-
dinge, Sweden. Of these, 123 were included in this study (40 patients were
excluded because of a lack of follow-up of study-speciﬁc samples). Patients
were followed for up to 8 years after HSCT. Patients with hematologic
malignancies as well as nonmalignant conditions (ie, benign hematologic,
metabolic, and primary immunodeﬁciency disorders) were included
(Table 1). The population was 67% male, and the ethnic composition was
75% European, 7% African, 15% Middle Eastern, and 3% of other ethnic
groups. The study was approved by the Regional Ethical Review Board in
Stockholm.Calcidiol at baseline P
50 nM (n ¼ 38)
5 (0-15) .03
) 26 (68%)/12 (32%)
17.0 (13.1-26.7) <.01
34 (89%) .008
0 <.0001
3 (8%)
1 (3%)
15 (39%)
2/6 (5%/16%)
0
0
13 (34%) <.001
2 (5%)
) 20 (53%)/18 (47%) .10
7 (18%)
19 (50%)
1 (3%)
7 (18%)
1 (3%)
3 (8%)
29 (76%)
22 (0-46)
8 (21%)
14 (37%)
19 (50%)
5 (13%)
29 (76%)
5 (13%)
4 (11%)
5.2 (.4-34)
5.5 (.1-15)
29 (76%)
5 (13%)
3 (8%)
1 (3%)
15 (39%)
5 (13%)
18 (47%)
6/32
29 (76%)
16 (42%)
88 (50-100) .04
atic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic
busulfan; Flu, ﬂudarabine; Treo, treosulfan; ATG, antithymocyte globuline
nor; MM, HLA-mismatched donor; PBSC, peripheral blood stem cells; CsA,
ars.
Figure 1. (A) Levels of calcidiol remained signiﬁcantly higher in the group that
had sufﬁcient levels before HSCT (baseline >50 nmol/L) during the ﬁrst
6 months of post-HSCT follow-up. (B) Time of year at transplantation had a
signiﬁcant impact on levels of calcidiol at baseline: patients who underwent
transplants in the ﬁrst 2 quarters of the year had signiﬁcantly lower levels than
those in the 2 last quarters.
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The HSCT procedure and conditioning regimens were published previ-
ously [11], and treatment data are presented in Table 1. Myeloablative
conditioning was applied in 82 transplants (67%). Mainly, cyclosporine A and
methotrexate (n ¼ 81, 66%) were used as GVHD prophylaxis. Other patients
received cyclosporine A and prednisolone (n ¼ 17, 14%), tacrolimus and
sirolimus (n ¼ 21, 17%), or other combinations (n ¼ 4, 3%). Antithymocyte
globulin serotherapy was given to patients (n ¼ 96, 78%) with unrelated
donors or nonmalignant disorders. Cotrimoxazole was used as Pneumocystis
jiroveci prophylaxis. In patients who developed hypogammaglobulinemia
(ie, plasma IgG < 4 g/L) post-HSCT, IgG substitution was applied as previ-
ously described [12].
Deﬁciencies in vitamin D levels were neither assessed nor treated
routinely. However, some children received vitamin D substitution because
of the following conditions: age <2 years, seizures, nephrologic disease, or
deteriorated calcium levels.
Data Collection
Data on each patient were obtained from medical records and patient
databases. The collected data included basic parameters (eg, sex, age at
transplantation, ethnicity), transplant characteristics (eg, diagnosis, condi-
tioning, GVHD prophylaxis, donor source, cell dose), and outcome param-
eters (eg, survival, rejection, relapse, number of infections, GVHD). Data on
vitamin D substitution (daily doses and length of treatment), immuno-
globulin substitution (number of treatments), and total parenteral nutrition
(length of treatment) were extracted from medication administration re-
cords. To verify the reproducibility of the abstracted data, 10 cases were
selected randomly and reabstracted by different researchers. Complete
agreement between the abstractions was conﬁrmed.
Outcome Data
Concentration of calcidiol (25-OH vitamin D3) in serum is widely
regarded as the optimal indicator of vitamin D status. In this study vitamin D
insufﬁciency, also referred to as hypovitaminosis D, was deﬁned as a calci-
diol level <50 nmol/L at baseline (ie, the ﬁrst sample, before the start of
conditioning regimen) [10].
Chosen endpoints in this study were as follows: presence of acute GVHD
(aGVHD; grades I to IV following international criteria [13]), presence of
chronic GVHD (cGVHD; deﬁned by international criteria [14]), immune re-
covery (lymphocyte and neutrophil granulocyte counts and measurements
of immunoglobulins), presence of infections (as explained below), overall
survival (OS), rejection (deﬁned as progressive mixed chimerism reaching
>95% recipient-derived cells in the lineage of interest), and relapse (deﬁned
by criteria in current protocols from the Nordic Society of Pediatric Hema-
tology and Oncology [www.nopho.org]).
Infections were recorded if they were registered in the patient’s medical
record by a physician. Bacterial and fungal infections required that positive
cultures were recorded. Viral infections required positive diagnostics unless
the clinical presentation was typical (eg, seasonal viral gastroenteritis).
Documented infections that could not be classiﬁed as bacterial, viral, or
fungal were denominated as other infections. Reactivation of cytomegalo-
virus (CMV) and Epstein-Barr virus (EBV) was distinguished from other viral
infections and deﬁned as 1000 viral DNA copies/mL in serum and in whole
blood. Treatment was initiated when viral DNA copies reached 2000 and
10,000 DNA copies/mL for CMV and EBV, respectively.
Clinical Chemistry
Full blood counts and immunoglobulin levels were obtained from the
medical records. Serum samples were collected prospectively before the
start of the conditioning regimen and post-HSCT (þ3, 6, and 12months), and
these were cryostored at 20C for analysis of total calcidiol by a compet-
itive chemiluminescence assay (Liaison XL; DiaSorin Inc., Stillwater, MN). All
laboratory procedures were carried out using accreditedmethodology at the
Department of Clinical Chemistry in the Karolinska University Laboratory,
Karolinska University Hospital. The accrediting authority was the Swedish
Board for Accreditation and Conformity Assessment (Swedac).
Statistics
Continuous variables and proportions were compared using the Mann-
Whitney U-test and the chi-square test, respectively. GVHD, relapse, and
rejectionwere estimated using an estimator of cumulative incidence curves,
taking competing events into consideration [15,16]. The Cox regression
method was used in the predictive analysis for OS and relapse-free survival,
whereas the method outlined by Fine and Gray [17] was used for predictive
analysis regarding GVHD and relapse. Factors included were donor and
recipient age, donor type, HLA match, disease stage (ie, early represents ﬁrst
complete remission/ﬁrst chronic phase and nonmalignant, whereas late
represents other cases), GVHD prophylaxis, nucleated cell dose, CD34þ celldose, stem cell source, reduced-intensity conditioning versus myeloablative
conditioning, total body irradiation versus no total body irradiation,
antithymocyte globulin versus no antithymocyte globulin, European versus
non-European origin, and calcidiol level. Statistical signiﬁcance was set at
P < .05. Analysis was performed using the cmprsk software package (The
R Project for Statistical Computing, http://www.r-project.org), S-Plus 6.2
software (TIBCO Software, Inc., Boston, MA), and Statistica software (Stat-
Soft, Inc., Tulsa, OK).RESULTS
Vitamin D Levels and Demographics
Patients were divided into 2 cohorts based on calcidiol
level at baseline (ie, pre-HSCT): low level (<50 nmol/L) and
sufﬁcient level (50 nmol/L). The mean calcidiol levels at
baseline were 33 nmol/L (range, 13 to 49) in the low level
group and 63 nmol/L (range, 50 to 97) in the sufﬁcient level
group. Calcidiol levels remained signiﬁcantly higher in the
sufﬁcient level group at least until the 6-month post-HSCT
(Figure 1A). No signiﬁcant association could be found be-
tween sample storage time and calcidiol levels (data not
shown).
Patients with low levels were older than patients with
sufﬁcient levels (mean, 10 versus 5 years; P ¼ .025). More
patients also had myelodysplastic syndrome with sufﬁcient
calcidiol levels (P < .001). No differences in other character-
istics were seen between the groups (Table 1). The season of
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patients who underwent transplants from January through
June had signiﬁcantly lower levels than patients who had
transplants in July through December (P ¼ .002; Figure 1B).
The distribution of ethnic origins differed between the
groups (Table 1). Patients of African descent all had low
calcidiol levels (11% versus 0%, P < .0001), whereas patients
with European descent were less prone to be deﬁcient (67%
versus 89%, P ¼ .008).
Vitamin D Levels, GVHD, and Immune Recovery
aGVHD occurred in 62 patients, corresponding to 50% of
the patients, of which 43 patients (35%) suffered fromFigure 2. (A) Moderate to severe aGVHD (grades II to IV) occurred more
commonly among patients with sufﬁcient levels of calcidiol at baseline
(>50 nmol/L). (B) Absolute neutrophil count rose faster during the ﬁrst
3 months post-HSCT among patients with sufﬁcient levels of calcidiol at
baseline. (C) Levels of IgG were signiﬁcantly lower in a group with calcidiol
above 75 nmol/L at baseline than in other groups.moderate to severe aGVHD (grades II to IV). In the sufﬁcient
calcidiol baseline level group, moderate to severe aGVHD
occurred more frequently than in the low baseline group
(47% versus 30%, P ¼ .05; Figure 2A). Multivariate analysis
revealed that late disease stage was associated with grades II
to IV aGVHD in malignancies, whereas sufﬁcient calcidiol
levels at baseline displayed a trend toward statistical signif-
icance (Table 2). cGVHD occurred in 17 patients (14%), with
no signiﬁcant difference between the low and sufﬁcient
calcidiol levels groups. However, comparing patients with
moderate to severe cGVHD with those without cGVHD
revealed a signiﬁcant difference in calcidiol levels at
6 months post-HSCT (23 nmol/L [range, 18 to 24] versus
37 nmol/L [range, 10 to 80], P ¼ .004).
Neutrophil granulocytes (measured as absolute neutro-
phil count) rose signiﬁcantly faster during the ﬁrst 3 months
post-HSCT among patients with sufﬁcient calcidiol levels at
baseline. During the next months no signiﬁcant difference
was observed (Figure 2B). Baseline calcidiol levels had no
signiﬁcant impact on lymphocytes or immunoglobulin levels
(IgG, IgM, and IgA) post-HSCT. Only when comparing a group
of patients with the highest baseline levels of calcidiol
(>75 nmol/L, n ¼ 11) with the insufﬁcient group or a middle
group (with baseline calcidiol levels 50 to 74 nmol/L, n ¼ 27)
were signiﬁcantly lower IgG levels at HSCT observed
(Figure 2C). However, this difference in IgG levels did not
remain over time post-HSCT. IgG substitution was
more common in the calcidiol sufﬁcient group (76% versus
56%, P ¼ .04).Vitamin D and Infections
The number of observed clinical infections did not differ
signiﬁcantly between groups. In both groups most patients
suffered from 1 to 4 infections during the ﬁrst year post-
HSCT. Data on speciﬁc viral infections did not show
signiﬁcant differences other than lower incidence of herpes
simplex virus and varicella zoster virus at 3 months post-
HSCT in the sufﬁcient level group (35% versus 27%, P ¼ .05
and 37% versus 25%, P ¼ .04, respectively).
The number of patients reactivating CMV or requiring
treatment against CMV did not differ between the low level
and the sufﬁcient level group (29% versus 34% and 22% versus
26%, respectively). Likewise, the number of patients reac-
tivating EBV or requiring treatment against EBV did not differ
between the groups (21% versus 18% and 9% versus 8%,Table 2
Risk Factor Analysis* for aGVHD, Mortality, Relapse, and Transplant Failure
HR 95% CI P
aGvHD grades II-IV, all
Calcidiol > 50 nmol/L 1.72 .96-3.13 .065
Late disease 2.59 1.42-4.71 .002
Mortality, malignancies
Calcidiol > 50 nmol/L .15 .04-.57 .005
URD 3.77 1.11-12.8 .03
MDS 2.93 1.09-7.88 .03
Relapse, malignancies
Calcidiol > 50 nmol/L .08 .01-.63 .02
Transplant failure,y malignancies
Calcidiol > 50 nmol/L .14 .04-.50 .002
URD 3.58 1.23-10.4 .02
HR indicates hazards ratio; 95% CI, 95% conﬁdence interval; Late disease,
beyond ﬁrst complete remission/ﬁrst chronic phase; URD, unrelated donor.
* Corrected for differences in the characteristics, such as age, stage and
myelodysplastic syndrome.
y That is, relapse or death.
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serologic EBV status of donor and recipientweremismatched.
Vitamin D and Survival
OS in all patients did not differ signiﬁcantly in the low level
and sufﬁcient level groups (69% versus 87%). Also, OS did not
differ between patients with nonmalignant and malignant
diseases (87% in both groups). However, in patients with
malignant diseases, sufﬁcient calcidiol levels were associated
with better OS (87% versus 50%, P ¼ .01; Figure 3A).
There was no difference in treatment-related mortality
between the groups. In multivariate analysis of patients with
malignancies, a baseline calcidiol level >50 nmol/L was
associated with better OS, whereas unrelated donor and
myelodysplastic syndrome carried an increased risk for
mortality (Table 2). Although graft rejection did not occur
among patients in the sufﬁcient level group, 11% of patients
in the low level group rejected their grafts (P ¼ .06).
Relapse was more common among patients in the low
level group (33% versus 4%, P ¼ .03; Figure 3B). The multi-
variate regression model found that only the baseline calci-
diol level was signiﬁcantly associated with relapse
(protective) (Table 2). Relapse-free survival was signiﬁcantly
better in patients with sufﬁcient levels of calcidiol than
among patients with insufﬁcient levels (87% versus 41%,
P ¼ .002). Factors affecting transplant failure (ie, relapse or
death) in multivariate analysis were calcidiol level
>50 nmol/L at baseline (protective) and the use of an unre-
lated donor (risk) (Table 2).
DISCUSSION
The steroid hormone vitamin D is known to affect
immunologic processes [18], and, more recently, novelFigure 3. (A) In patients with malignant diseases, sufﬁcient calcidiol levels at
baseline (<50 nmol/L) were associated with greater OS. (B) Relapse was less
common among patients with sufﬁcient levels of calcidiol at baseline.mechanisms of action have been uncovered [3,4,18,19]. A few
studies suggest that sufﬁcient vitamin D levels may beneﬁt
patients undergoing HSCT [6,7,9]. In the present study we
followed 123 pediatric patients for up to 8 years post-HSCT
and correlated their baseline vitamin D status with a num-
ber of clinical outcomes. This is one of the ﬁrst reports in
which such associations are analyzed in detail.
We chose to deﬁne hypovitaminosis D as baseline calci-
diol (25[OH]-vitamin D) levels in serum below 50 nmol/L,
based on previous reports [12-14]. To date, consensus
regarding sufﬁcient levels is not established, but 75 nmol/L
or higher is commonly referred to as sufﬁcient in both chil-
dren and adults. Most recommendations are based on
studies of vitamin D and bone health; however, levels for
optimal inﬂuence on immunologic processes might be even
higher [20].
Young children, institutionalized patients, and non-
Western immigrants are usually regarded as risk groups for
hypovitaminosis D [21], but up to one-third of American
children and adolescents are also vitamin D deﬁcient with
seasonal variation [20,22]. In adult HSCT patients, numbers
are even higher; 70% to 89% of adult HSCT patients are
vitamin D deﬁcient before transplantation [23,24]. Duncan
et al. [9] followed 67 pediatric HSCT patients and found that
37% were deﬁcient at baseline, but in the subgroup of pa-
tients11 years old, 67% were deﬁcient, a ﬁgure that accords
with our ﬁndings (69%). HSCT patients are more prone to
develop hypovitaminosis D as a result of sun avoidance,
hospitalization, corticosteroid treatment, and diminished
intestinal uptake affected by GVHD and bacterial overgrowth
[9,25-27]. The lowest baseline levels in our study were found
in patients who underwent transplants during winter,
spring, and early summerdthat is, before opportunities for
sun exposure in northern latitudes become plentiful enough
to raise serum levels. In brief, our patients with insufﬁcient
baseline levels were older, more often of non-European
origin, and underwent transplants during winter and
spring, when vitamin D levels tend to be low. The groups did
not differ signiﬁcantly regarding HSCT parameters (eg, con-
ditioning, donor, stem cell source). Comparable and
diverging results were reported by others [9,24,25,28] and
might be explained by study population differences. How-
ever, it is clear that certain patients are at risk for developing
hypovitaminosis D that easily can be treated.
Because GVHD is the major obstacle to successful HSCT,
great efforts are undertaken to understand and modify this
complication. T-lymphocyte responses, which can be modi-
ﬁed by vitamin D, are central in the GVHD pathogenesis.
Pakkala et al. [29] showed that a vitamin D analog decreased
signs of aGVHD inmice, probably by down-regulation of both
T-lymphocyte activation and inﬂammatory effector mecha-
nisms. In vitro studies have shown that an active vitamin D
dose dependently inhibits mixed lymphocyte cultures [30]
and affects dendritic cell maturation, resulting in a T helper
cell type 2 polarized T-lymphocyte population [6]. Active
vitamin D also alters dendritic cell surface phenotype and
morphology, which may compromise contacts between
dendritic cell and T lymphocytes and thereby diminish
interaction and T-lymphocyte cytokine secretion [31].
Together, such conditions would lead to tolerizing rather
than to stimulated T-lymphocyte populations.
These ﬁndings serve as a rationale for treating or pre-
venting GVHD by upholding normal levels of vitamin D.
Rosenblatt et al. reported 2 cases of adult patients suffering
from corticosteroid-refractory GVHD in which improvement
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dicting this, the frequency of aGVHD was higher and that of
cGVHD lower in patients with sufﬁcient calcidiol levels in our
material. Our ﬁnding emphasizes the different pathogenesis
of the 2 forms of GVHD but may also underline the fact that
vitamin D has dual rolesdboth immunostimulatory and
immunoinhibitory. The linkage between vitamin D levels
and cGVHD is supported by observations in adult HSCT,
becasue low pre-HSCT vitamin D levels were a signiﬁcant
factor associated with cGVHD. Patients receiving vitamin D
substitution post-HSCT suffered fewer cGVHD relapses and
could more often be taken off immunosuppressive treatment
[7,32]. We found that calcidiol levels were signiﬁcantly lower
in patients withmoderate to severe cGVHD at 6months post-
HSCT than theywere in patients without cGVHD orwithmild
disease (P ¼ .004 and P ¼ .005, respectively). The difference
can partially be explained by an impaired nutritional status
and lower sun exposure among the severely ill patients, but
because low levels of calcidiol in this context are unfavorable,
substitution with cholecalciferol may be considered.
Systemic or locally produced calcitriol (1,25[OH]2-vitamin
D) affects several types of immune cells. In addition to acting
as an inhibitor on parts of the adaptive immune system,
active vitamin D can stimulate monocyte proliferation and
enhance synthesis of the antibacterial peptide LL-37 (human
cathelicidin) [3,4,33]. The effect of vitamin D on immune
reconstitution after HSCT is not well described. In our ma-
terial, neutrophil counts were signiﬁcantly higher during the
ﬁrst 3 months post-HSCT in the sufﬁcient level group. This
might be interpreted as a vitamin Demediated stimulatory
effect in the early phases of immune recovery. Moreover,
aGVHD appears during this period, and, as described above,
higher calcidiol levels were associated with an increased
frequency of aGVHD. The difference in neutrophil was,
however, not sustained during the later phase of follow-up.
Calcitriol has been shown to suppress B-lymphocyte prolif-
eration, plasma cell differentiation, and IgG secretion [3,4], a
ﬁnding that aligns with our own. Patients with the highest
levels of calcidiol at baseline had the lowest IgG levels at
follow-up and more commonly needed IgG replacement.
However, these patients tended to be younger, which may be
why the physiologic variation in IgG levels might inﬂuence
the ﬁnding. A faster normalization of immune cell counts
might have implications for infection susceptibility, but no
signiﬁcant impact was discerned in our material. One reason
for this could be the overall relatively low baseline calcidiol
levels, because protective effects on infection susceptibility
might not be seen unless levels of calcidiol are well above
75 nmol/L [7,19].
In the patient group as a whole, OS did not differ between
groups, probably because of the favorable survival rate in
patients with nonmalignant disease. However, in patients
with malignancies, OS was signiﬁcantly higher in the group
that had sufﬁcient baseline calcidiol levels. This ﬁnding is at
odds with data from another recent study, however,
considering adult patients and no signiﬁcant difference
related to vitamin D levels was observed [32]. The difference
in OS between the 2 groups in our study was mainly due to a
signiﬁcantly increased relapse rate in the insufﬁcient level
group, suggesting that vitamin D played a beneﬁcial role.
Thus, the combination of better OS and less frequent relapse
may suggest that vitamin D exerts immunostimulatory ef-
fects, mediating the expansion of alloreactive cells, including
those with a capacity to kill malignant cells (ie, graft-versus-
leukemia reaction). An alternative explanation concerningthe apparent effect on OS might be that calcidiol levels
constitute a surrogate marker for patient well-being and
overall health status immediately before HSCT. However,
there was no difference in pre-HSCT Lansky/Karnofsky sores,
and in the multivariate analysis, sufﬁcient calcidiol levels
remained signiﬁcantly associated with better OS, which
supports a true association. Rejection occurred only among
patients in the insufﬁcient level group in our material. This
also suggests a beneﬁcial role for vitamin D in allograft sur-
vival. In analogy with the hypothesis of OS and relapse,
higher vitamin D levels might stimulate the expansion of
alloreactive cells killing recipient cells, giving rise to full
donor chimerism development. These ﬁndings merit further
experimental studies, as well as clinical trials in larger pa-
tient cohorts.
As in all retrospective studies, our data also have to be
interpreted with caution. There are a restricted number of
patients with uneven distributions between the groups, and,
as mentioned above, there is no general consensus regarding
the deﬁnition of hypovitaminosis D. However, there was
consistency in how the patients were cared for (ie, single
intuition with a solid medical team), and the distribution of
hypovitaminos D cases are interesting per se.
We conclude that vitamin D levels seem to affect the
clinical course of children undergoing HSCT. Hypovitami-
nosis D was associated with slower recovery of neutrophil
granulocyte counts and increased risk of death, relapse, and
cGVHD. aGVHD, however, occurred more frequently among
patients with sufﬁcient baseline levels of vitamin D, whereas
treatment-related mortality was not affected. Effects on
infection rates were not obvious. However, because obser-
vational studies cannot indicate causality, further stud-
iesdpreferably with an interventional designdare needed
to establish the ways that vitamin D, as well as other
micronutrients, inﬂuence immunologic processes in HSCT
and subsequent outcomes.ACKNOWLEDGMENTS
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